Abstract
Purpose: Triamcinolone acetonideextended-release (TA-ER) is a polylactic-co-glycolic acid (PLGA) microspherepreparation of triamcinolone acetonide, FDA-approved for treatment of knee paindue to OA. Following intra-articular injection with TA-ER, triamcinoloneacetonide has been found to persist in the synovial fluid through 16-weekfollow-up. While the efficacy of TA-ER on reducing pain due to knee OA has beenreported, the effects on physical performance have not been fully investigated.Given the incomplete association between reduction in pain and reduction in functionallimitations, the primary aim of this study was to demonstrate theeffects of intra-articular injection of TA-ER on OARSI-recommended physicalperformance measures (30-second chair stand test, stair ascent time, and 40mfast-paced walking time) in adults with bilateral symptomatic knee OA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
